SCHEMBL19254079

SCHEMBL19254079

CC(C)(C)c1ccc(C(C)(C)CCC(C)(C)c2ccc(C(C)(C)CCC(C)(C)c3ncnc(C(C)(C)C)n3)cc2)nc1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18857245 0.87 APP (0.36)
SCHEMBL24926664 0.83 ALDH1A1 (0.37)
SCHEMBL25568917 0.82 ALDH1A1 (0.36)
SCHEMBL24926243 0.79 TSHR (0.34)
SCHEMBL24234525 0.74 TSHR (0.40)
SCHEMBL21791916 0.73
SCHEMBL22249892 0.73
SCHEMBL24127078 0.72 TSHR (0.37)
SCHEMBL27024927 0.71 TSHR (0.34)
SCHEMBL15499726 0.70 LOXL2 (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170231986-A1 Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 Inhibitor ACERTA PHARMA B.V. (NL) 2017-08-17 US disclosed